In this study, we developed acellular pertussis vaccines using liposome + QS-21 adjuvant and compared this novel adjuvant combination with traditional aluminum hydroxide adjuvant by studying antigen-specific antibodies, PT-neutralizing antibodies, antibody subtypes, and tissue-resident memory T cell levels. This evidence concerns the gene F2 and pertussis.